Base de dados : MEDLINE
Pesquisa : C07.465.815.929 [Categoria DeCS]
Referências encontradas : 4305 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 431 ir para página                         

  1 / 4305 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29258641
[Au] Autor:Hannah VE; O'Donnell L; Robertson D; Ramage G
[Ti] Título:Denture Stomatitis: Causes, Cures and Prevention.
[So] Source:Prim Dent J;6(4):46-51, 2017 Dec 01.
[Is] ISSN:2050-1684
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Removable dentures are worn by 20% of the UK population and two thirds of these individuals have denture stomatitis. Poor oral hygiene is commonplace among this group, as is smoking and xerostomia, which also contribute to the development of denture stomatitis. A complex polymicrobial biofilm is able to proliferate on the surface of denture materials and matures to form visible denture plaque. This denture plaque biofilm stimulates a local inflammatory process that is detectable clinically as erythema, and hyperplasia. Systemically, denture plaque represents a potential risk factor for systemic disease, in particular aspiration pneumonia. Respiratory pathogens have been detected in the denture plaque and overnight denture wear has been linked to an increased risk of aspiration pneumonia. There is a general lack of evidence on the adequate management of denture stomatitis and we present a protocol for use in the primary care setting.
[Mh] Termos MeSH primário: Odontologia Geral
Higiene Bucal
Estomatite sob Prótese
[Mh] Termos MeSH secundário: Biofilmes
Placa Dentária/complicações
Seres Humanos
Fatores de Risco
Fumar/efeitos adversos
Estomatite sob Prótese/etiologia
Estomatite sob Prótese/microbiologia
Estomatite sob Prótese/prevenção & controle
Estomatite sob Prótese/terapia
Xerostomia/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1308/205016817822230175


  2 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29251635
[Au] Autor:Cullen L; Baumler S; Farrington M; Dawson C; Folkmann P; Brenner L
[Ad] Endereço:Laura Cullen is an evidence-based practice scientist, Sharon Baumler is a staff nurse, Michele Farrington is a clinical health care research associate, Cindy Dawson is the interim chief nursing officer, Peggy Folkmann is a nurse clinician (retired), and Loraine Brenner is a nurse clinician, all in the Department of Nursing Services and Patient Care at the University of Iowa Hospitals and Clinics, Iowa City. Contact author: Laura Cullen, laura-cullen@uiowa.edu. The authors gratefully acknowledge Jimmy Reyes, DNP, RN, AGNP, for his translation of the oral care insert into Spanish, and the DAISY Foundation for the partial funding it provided. The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
[Ti] Título:CE: Oral Care for Head and Neck Cancer Symptom Management.
[So] Source:Am J Nurs;118(1):24-34, 2018 Jan.
[Is] ISSN:1538-7488
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:: An evidence-based practice change at a radiation oncology center in a large academic medical center was designed to reduce the severity of oral mucositis in adults receiving radiation treatment for head and neck cancer. In the intervention described, patients were given newly created oral care kits and educational materials to improve their oral hygiene. Evaluations were conducted at three points during the project (before radiation treatment, during week 4 to 5 of treatment, and one month after treatment). At week 4 to 5-when the severity of oral mucositis is expected to peak-patients reported improved oral hygiene practices and reduced oral mucositis severity. The authors conclude that the use of these oral care kits and educational materials lessened the effects of oral mucositis during and after radiation treatment.
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço/radioterapia
Higiene Bucal
Estomatite/etiologia
Estomatite/prevenção & controle
[Mh] Termos MeSH secundário: Atitude do Pessoal de Saúde
Comportamento Cooperativo
Prática Clínica Baseada em Evidências
Seres Humanos
Relações Interprofissionais
Educação de Pacientes como Assunto
Avaliação de Programas e Projetos de Saúde
Radioterapia/efeitos adversos
Xerostomia/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM; N
[Da] Data de entrada para processamento:171219
[St] Status:MEDLINE
[do] DOI:10.1097/01.NAJ.0000529694.30568.41


  3 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29172327
[Au] Autor:Noone J; Barclay C
[Ti] Título:Head and Neck Cancer Patients ­ Information for the General Dental Practitioner.
[So] Source:Dent Update;44(3):209-10, 213-5, 2017 Mar.
[Is] ISSN:0305-5000
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Salivary gland damage is the most common adverse effect associated with radiation therapy to the head and neck. A combination of hyposalivation and dietary changes, with a reduced emphasis on oral hygiene practices can contribute to a massive increase in a person's caries risk status. This can be further complicated by limited mouth opening. To enable optimal dental care for head and neck cancer patients before, during and after radiation therapy, patients must be informed and educated about the potential risks of dental caries and the preventive strategies available. All patients should receive a pre-radiotherapy dental assessment by a Restorative Dentistry Consultant. This information will be delivered to the patient, often at an emotionally charged time, and can be lost amongst all the information related to other aspects of his/her cancer management. General Dental Practitioners (GDPs) are therefore in a pivotal position to reiterate this information post radiation therapy and ensure compliance with preventive strategies, with the overall aim to improve quality of life and avoid the need for future extractions and the resulting risk of osteoradionecrosis. Clinical relevance: This article highlights the GDP's role in the shared management of head and neck cancer patients who have received radiotherapy as part of their cancer treatment. The critical issue of dental caries, one of the late effects of radiation-induced hyposalivation, will be focused upon. Other side-effects, such as trismus and osteoradionecrosis, will also be discussed. This article aims to supply GDPs with accurate information to provide to their patients with post radiation therapy, whilst highlighting what treatment is within their remit and when it may be appropriate to refer.
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço/radioterapia
Lesões por Radiação/etiologia
[Mh] Termos MeSH secundário: Cárie Dentária/etiologia
Odontologia Geral
Seres Humanos
Lesões por Radiação/prevenção & controle
Doenças das Glândulas Salivares/etiologia
Xerostomia/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  4 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29235767
[Au] Autor:Brown RS; Rhodes BH; Siewe MS; Matthews TJ
[Ti] Título:Severe Xerostomia Secondary to Anticholinergic Drug Therapy: Case Report.
[So] Source:Dent Today;36(2):136-8, 2017 Feb.
[Is] ISSN:8750-2186
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antagonistas Colinérgicos/efeitos adversos
Ácidos Mandélicos/efeitos adversos
Incontinência Urinária/tratamento farmacológico
Xerostomia/induzido quimicamente
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholinergic Antagonists); 0 (Mandelic Acids); K9P6MC7092 (oxybutynin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:D
[Da] Data de entrada para processamento:171214
[St] Status:MEDLINE


  5 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29187918
[Au] Autor:Mohsin AHB; Reddy V; Kumar P; Raj J; Babu SS
[Ad] Endereço:Department of Prosthodontics, Sri Sai College of Dental Surgery, Vikarabad, India.
[Ti] Título:Evaluation of wetting ability of five new saliva substitutes on heat-polymerized acrylic resin for retention of complete dentures in dry mouth patients: a comparative study.
[So] Source:Pan Afr Med J;27:185, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicação:Uganda
[La] Idioma:eng
[Ab] Resumo:Introduction: The aim of this study was to evaluate & compare the wetting ability of five saliva substitutes & distilled water on heat-polymerized acrylic resin. Contact angle of the saliva substitute on denture base can be taken as an indicator of wettability. Good wetting of heat-polymerized acrylic resin is critical for optimum retention of complete dentures. Methods: Two hundred & forty samples of heat-polymerized acrylic resin were fabricated using conventional method. 240 samples divided into 6 groups with 40 samples in each group. Advancing & Receding contact angles were measured using Contact Angle Goniometer & DSA4 software analysis. Results: Anova test was carried out to test the significance in difference of contact angle values in the six groups. The mean of advancing angle values & mean of receding angle values of all the six groups has shown statistically significant difference between the groups. The mean of angle of hysteresis values of all the six groups are statistically not significant between the groups. A multiple comparison using Bonferroni's test was carried out to verify the significance of difference between the contact angles in a pair of groups. Statistically significant difference was seen when Aqwet (Group II) was compared to Distilled water (Group I), Wet Mouth (Group III), E-Saliva (Group IV), Biotene (Group V), and Moi-Stir (Group VI). Conclusion: The contact angles of five saliva substitutes and distilled water were measured and compared. Group II (AQWET) has the lowest advancing and receding contact angle values and the highest angle of hysteresis on heat-polymerized acrylic resin. Based on contact angle values, Group II (AQWET) has the best wetting ability on heat-cured acrylic resins. The ability of saliva to wet the denture surface is one of the most important properties for complete denture retention in dry mouth cases.
[Mh] Termos MeSH primário: Resinas Acrílicas/química
Retenção de Dentadura
Prótese Total
Saliva Artificial/química
[Mh] Termos MeSH secundário: Bases de Dentadura
Temperatura Alta
Seres Humanos
Saliva/metabolismo
Molhabilidade
Xerostomia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acrylic Resins); 0 (Saliva, Artificial)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.185.9098


  6 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28972794
[Au] Autor:Nevens D; Nuyts S
[Ad] Endereço:Department of Radiation Oncology, KU Leuven-University of Leuven, University Hospitals Leuven , Leuven, Belgium.
[Ti] Título:Can sparing of the superficial contralateral parotid lobe reduce xerostomia following radiotherapy for head and neck cancer?
[So] Source:Br J Radiol;90(1080):20170596, 2017 Dec.
[Is] ISSN:1748-880X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The purpose of this study is to see whether sparing the superficial contralateral parotid lobe can help limiting xerostomia following radiotherapy for head and neck cancer. METHODS: 88 patients that were included in two prospective randomized studies were analysed in the current study. Using the dosimetry of both the parotid glands, we divided our patients in four groups. Group 1 includes patients where we were able to reduce the radiation dose below the threshold in order to spare both the ipsilateral and contralateral parotid glands, Group 2 consists of patients where only the contralateral parotid gland could be spared. Group 3 consists of patients where only the contralateral superficial parotid lobe could be spared, while in Group 4 not even the contralateral superficial lobe could be spared. RESULTS: When we compared Group 1 and Group 2, we did not observe a significant difference between both groups in terms of xerostomia scores at 6 or 12 months. When we compared these groups with Group 3, we observed significant differences with more xerostomia in Group 3 where only the contralateral superficial lobe was spared. A significant difference was also observed between Group 3 and Group 4 with more xerostomia in Group 4. CONCLUSION: Sparing of just one superficial parotid lobe results in less xerostomia when compared to not sparing any lobe of both parotid glands. Advances in knowledge: When sparing of the whole contralateral parotid gland is not possible, delineating both the superficial parotid glands and trying to spare at least one of them can mean a way forward in limiting xerostomia in head and neck cancer patients treated with radiotherapy.
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço/radioterapia
Tratamentos com Preservação do Órgão/métodos
Órgãos em Risco/efeitos da radiação
Glândula Parótida/efeitos da radiação
Xerostomia/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Feminino
Seguimentos
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Dosagem Radioterapêutica
Resultado do Tratamento
Xerostomia/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171004
[St] Status:MEDLINE
[do] DOI:10.1259/bjr.20170596


  7 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28767676
[Au] Autor:Lima DLF; Carneiro SDRM; Barbosa FTS; Saintrain MVL; Moizan JAH; Doucet J
[Ad] Endereço:Dental School Undergraduation and Graduation Programs, University of Fortaleza - Unifor, Fortaleza, Brazil.
[Ti] Título:Salivary flow and xerostomia in older patients with type 2 diabetes mellitus.
[So] Source:PLoS One;12(8):e0180891, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To assess salivary flow in older patients with type 2 diabetes mellitus (DM2) and its association with xerostomia. METHODS: Cross-sectional clinical study conducted with older patients diagnosed with type 2 diabetes for at least one year receiving treatment at the Integrated Center for Diabetes and Hypertension of Ceará (CIHD) in the city of Fortaleza, Ceará, Northeastern Brazil. Oral clinical examination was carried out to assess the decayed, missing and filled teeth index (DMFT). Perception of the presence of xerostomia/dry mouth was assessed using the Visual Analogue Scale. Stimulated salivary flow was measured and samples were obtained using an extra-soft silicone device. RESULTS: 120 older patients with diabetes (60 insulin-dependent and 60 non-insulin-dependent) aged 65-91 years, with a mean age of 72.26 ± 6.53 years, were assessed. Of these, 111 (92.5%) presented a decrease in salivary flow while 59 (49.2%) reported moderate to severe xerostomia/dry mouth. The DMFT Index presented a mean of 27.53 ± 4.86 teeth. CONCLUSIONS: Reduced salivary flow was found in the group assessed in the present research; however, this finding is not in accordance with the perception of xerostomia/dry mouth reported by the patients.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/complicações
Salivação/fisiologia
Xerostomia/complicações
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Estudos Transversais
Diabetes Mellitus Tipo 2/tratamento farmacológico
Diabetes Mellitus Tipo 2/patologia
Feminino
Seres Humanos
Insulina/uso terapêutico
Masculino
Glândulas Salivares/secreção
Perda de Dente/complicações
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170803
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180891


  8 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28759822
[Au] Autor:Strojan P; Hutcheson KA; Eisbruch A; Beitler JJ; Langendijk JA; Lee AWM; Corry J; Mendenhall WM; Smee R; Rinaldo A; Ferlito A
[Ad] Endereço:Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia. Electronic address: pstrojan@onko-i.si.
[Ti] Título:Treatment of late sequelae after radiotherapy for head and neck cancer.
[So] Source:Cancer Treat Rev;59:79-92, 2017 Sep.
[Is] ISSN:1532-1967
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Radiotherapy (RT) is used to treat approximately 80% of patients with cancer of the head and neck. Despite enormous advances in RT planning and delivery, a significant number of patients will experience radiation-associated toxicities, especially those treated with concurrent systemic agents. Many effective management options are available for acute RT-associated toxicities, but treatment options are much more limited and of variable benefit among patients who develop late sequelae after RT. The adverse impact of developing late tissue damage in irradiated patients may range from bothersome symptoms that negatively affect their quality of life to severe life-threatening complications. In the region of the head and neck, among the most problematic late effects are impaired function of the salivary glands and swallowing apparatus. Other tissues and structures in the region may be at risk, depending mainly on the location of the irradiated tumor relative to the mandible and hearing apparatus. Here, we review the available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.
[Mh] Termos MeSH primário: Neoplasias de Cabeça e Pescoço/mortalidade
Neoplasias de Cabeça e Pescoço/radioterapia
Lesões por Radiação/fisiopatologia
Radioterapia/efeitos adversos
[Mh] Termos MeSH secundário: Transtornos de Deglutição/epidemiologia
Transtornos de Deglutição/etiologia
Transtornos de Deglutição/fisiopatologia
Intervalo Livre de Doença
Relação Dose-Resposta à Radiação
Feminino
Neoplasias de Cabeça e Pescoço/patologia
Perda Auditiva/epidemiologia
Perda Auditiva/etiologia
Perda Auditiva/fisiopatologia
Seres Humanos
Masculino
Mandíbula/patologia
Mandíbula/efeitos da radiação
Osteonecrose/epidemiologia
Osteonecrose/etiologia
Osteonecrose/fisiopatologia
Prognóstico
Lesões por Radiação/epidemiologia
Tolerância a Radiação
Radioterapia/métodos
Dosagem Radioterapêutica
Medição de Risco
Análise de Sobrevida
Trismo/epidemiologia
Trismo/etiologia
Trismo/fisiopatologia
Xerostomia/epidemiologia
Xerostomia/etiologia
Xerostomia/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE


  9 / 4305 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28759701
[Au] Autor:Riley P; Glenny AM; Hua F; Worthington HV
[Ad] Endereço:Cochrane Oral Health, Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, JR Moore Building, Oxford Road, Manchester, UK, M13 9PL.
[Ti] Título:Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy.
[So] Source:Cochrane Database Syst Rev;7:CD012744, 2017 07 31.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Salivary gland dysfunction is an 'umbrella' term for the presence of either xerostomia (subjective sensation of dryness), or salivary gland hypofunction (reduction in saliva production). It is a predictable side effect of radiotherapy to the head and neck region, and is associated with a significant impairment of quality of life. A wide range of pharmacological interventions, with varying mechanisms of action, have been used for the prevention of radiation-induced salivary gland dysfunction. OBJECTIVES: To assess the effects of pharmacological interventions for the prevention of radiation-induced salivary gland dysfunction. SEARCH METHODS: Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 14 September 2016); the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 14 September 2016); MEDLINE Ovid (1946 to 14 September 2016); Embase Ovid (1980 to 14 September 2016); CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 14 September 2016); LILACS BIREME Virtual Health Library (Latin American and Caribbean Health Science Information database; 1982 to 14 September 2016); Zetoc Conference Proceedings (1993 to 14 September 2016); and OpenGrey (1997 to 14 September 2016). We searched the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases. SELECTION CRITERIA: We included randomised controlled trials, irrespective of their language of publication or publication status. Trials included participants of all ages, ethnic origin and gender, scheduled to receive radiotherapy on its own or in addition to chemotherapy to the head and neck region. Participants could be outpatients or inpatients. We included trials comparing any pharmacological agent regimen, prescribed prophylactically for salivary gland dysfunction prior to or during radiotherapy, with placebo, no intervention or an alternative pharmacological intervention. Comparisons of radiation techniques were excluded. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We included 39 studies that randomised 3520 participants; the number of participants analysed varied by outcome and time point. The studies were ordered into 14 separate comparisons with meta-analysis only being possible in three of those.We found low-quality evidence to show that amifostine, when compared to a placebo or no treatment control, might reduce the risk of moderate to severe xerostomia (grade 2 or higher on a 0 to 4 scale) at the end of radiotherapy (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.19 to 0.67; P = 0.001, 3 studies, 119 participants), and up to three months after radiotherapy (RR 0.66, 95% CI 0.48 to 0.92; P = 0.01, 5 studies, 687 participants), but there is insufficient evidence that the effect is sustained up to 12 months after radiotherapy (RR 0.70, 95% CI 0.40 to 1.23; P = 0.21, 7 studies, 682 participants). We found very low-quality evidence that amifostine increased unstimulated salivary flow rate up to 12 months after radiotherapy, both in terms of mg of saliva per 5 minutes (mean difference (MD) 0.32, 95% CI 0.09 to 0.55; P = 0.006, 1 study, 27 participants), and incidence of producing greater than 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; P = 0.004, 1 study, 175 participants). However, there was insufficient evidence to show a difference when looking at stimulated salivary flow rates. There was insufficient (very low-quality) evidence to show that amifostine compromised the effects of cancer treatment when looking at survival measures. There was some very low-quality evidence of a small benefit for amifostine in terms of quality of life (10-point scale) at 12 months after radiotherapy (MD 0.70, 95% CI 0.20 to 1.20; P = 0.006, 1 study, 180 participants), but insufficient evidence at the end of and up to three months postradiotherapy. A further study showed no evidence of a difference at 6, 12, 18 and 24 months postradiotherapy. There was low-quality evidence that amifostine is associated with increases in: vomiting (RR 4.90, 95% CI 2.87 to 8.38; P < 0.00001, 5 studies, 601 participants); hypotension (RR 9.20, 95% CI 2.84 to 29.83; P = 0.0002, 3 studies, 376 participants); nausea (RR 2.60, 95% CI 1.81 to 3.74; P < 0.00001, 4 studies, 556 participants); and allergic response (RR 7.51, 95% CI 1.40 to 40.39; P = 0.02, 3 studies, 524 participants).We found insufficient evidence (that was of very low quality) to determine whether or not pilocarpine performed better or worse than a placebo or no treatment control for the outcomes: xerostomia, salivary flow rate, survival, and quality of life. There was some low-quality evidence that pilocarpine was associated with an increase in sweating (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004, 5 studies, 389 participants).We found insufficient evidence to determine whether or not palifermin performed better or worse than placebo for: xerostomia (low quality); survival (moderate quality); and any adverse effects.There was also insufficient evidence to determine the effects of the following interventions: biperiden plus pilocarpine, Chinese medicines, bethanechol, artificial saliva, selenium, antiseptic mouthrinse, antimicrobial lozenge, polaprezinc, azulene rinse, and Venalot Depot (coumarin plus troxerutin). AUTHORS' CONCLUSIONS: There is some low-quality evidence to suggest that amifostine prevents the feeling of dry mouth in people receiving radiotherapy to the head and neck (with or without chemotherapy) in the short- (end of radiotherapy) to medium-term (three months postradiotherapy). However, it is less clear whether or not this effect is sustained to 12 months postradiotherapy. The benefits of amifostine should be weighed against its high cost and side effects. There was insufficient evidence to show that any other intervention is beneficial.
[Mh] Termos MeSH primário: Radioterapia/efeitos adversos
Doenças das Glândulas Salivares/prevenção & controle
Xerostomia/prevenção & controle
[Mh] Termos MeSH secundário: Amifostina/uso terapêutico
Medicamentos de Ervas Chinesas/uso terapêutico
Feminino
Fator 7 de Crescimento de Fibroblastos/uso terapêutico
Seres Humanos
Masculino
Pilocarpina/uso terapêutico
Qualidade de Vida
Protetores contra Radiação/efeitos adversos
Protetores contra Radiação/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Saliva Artificial
Doenças das Glândulas Salivares/etiologia
Glândulas Salivares/efeitos da radiação
Salivação/efeitos dos fármacos
Salivação/efeitos da radiação
Xerostomia/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Drugs, Chinese Herbal); 0 (Radiation-Protective Agents); 0 (Saliva, Artificial); 01MI4Q9DI3 (Pilocarpine); 126469-10-1 (Fibroblast Growth Factor 7); M487QF2F4V (Amifostine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170801
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD012744


  10 / 4305 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28721884
[Au] Autor:Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
[Ad] Endereço:Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Lineberger Comprehensive Cancer Center, University of North Carolina Hospitals, Chapel Hill, North Carolina. Electronic address: bchera@med.unc.edu.
[Ti] Título:Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
[So] Source:Int J Radiat Oncol Biol Phys;98(5):1022-1027, 2017 Aug 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE/OBJECTIVE(S): To estimate the association between different dose-volume metrics of the salivary glands and pharyngeal constrictors with patient reported severity of xerostomia/dysphagia in the setting of deintensified chemoradiation therapy (CRT). METHODS AND MATERIALS: Forty-five patients were treated on a phase 2 study assessing the efficacy of deintensified CRT for favorable-risk, HPV-associated oropharyngeal squamous cell carcinoma. Patients received 60 Gy intensity modulated radiation therapy with concurrent weekly cisplatin (30 mg/m ), and reported the severity of their xerostomia/dysphagia (before and after treatment) using the patient-reported outcome version of the Common Terminology Criteria for Adverse Events (CTCAE) (PRO-CTCAE). Individual patient dosimetric data of the contralateral parotid and submandibular glands and pharyngeal constrictors were correlated with changes in PRO-CTCAE severity. A change in severity (from baseline) of ≥2 was considered clinically meaningful. Associations between dose-volume metrics and patient outcomes were assessed with receiver operating characteristic (ROC) curve and logistic regression model. RESULTS: Six months after CRT, patients reporting <2 change in xerostomia severity (n=14) had an average D = 22 ± 9 Gy to the sum of the contralateral glands (parotid + submandibular) compared with the patients reporting ≥2 change (n=21), who had an average D = 34 ± 8 Gy. V15 to V55 for the combined contralateral glands showed the strongest association with xerostomia (area under the curve [AUC] = 0.83-0.86). Based on the regression analysis, a 20% risk of toxicity was associated with V15 = 48%, V25 = 30%, and D =21 Gy. Six months after CRT, patients reporting <2 change in dysphagia severity (n=26) had an average V55 = 76 ± 13 (%) to the superior pharyngeal constrictor compared with the patients reporting ≥2 change in severity (n=9), who had average V55 = 89 ± 13 (%). V55to V60 had the strongest association with dysphagia (AUC = 0.70-0.75). Based on the regression analysis, a 20% risk of toxicity was associated with V55 = 78%, V60 = 40%. The findings at 12 months were similar. CONCLUSIONS: After deintensified CRT, the rate of patient-reported xerostomia/dysphagia appears to be associated with the V15 of the combined contralateral salivary glands and V55 to V60 of the superior pharyngeal constrictors.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/terapia
Carcinoma de Células Escamosas/virologia
Quimiorradioterapia/efeitos adversos
Transtornos de Deglutição/etiologia
Neoplasias Orofaríngeas/terapia
Neoplasias Orofaríngeas/virologia
Papillomaviridae
Xerostomia/etiologia
[Mh] Termos MeSH secundário: Antineoplásicos/administração & dosagem
Área Sob a Curva
Quimiorradioterapia/métodos
Cisplatino/administração & dosagem
Esôfago/efeitos da radiação
Seres Humanos
Glândula Parótida/efeitos da radiação
Músculos Faríngeos/efeitos da radiação
Dosagem Radioterapêutica
Radioterapia de Intensidade Modulada/métodos
Índice de Gravidade de Doença
Glândula Submandibular/efeitos da radiação
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170720
[St] Status:MEDLINE



página 1 de 431 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde